ArticleNature communications2023
C
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 40 citations in OpenAlex.
- Computationally guided design of bioactive nanostructures for targeted clearance of amyloid-β aggregates in Alzheimer's disease.Nature nanotechnology · 2026Article
- Nanotechnology-based targeted delivery strategies for the treatment of Alzheimer's disease.Nanoscale advances · 2026Review
- Smart Drug-Delivery Approaches for Enhanced Management of Comorbid Conditions in Alzheimer's Disease.Life (Basel, Switzerland) · 2026Review
- A systematic review on competitive screening and independent variable unification focused on PAA structural parameter calculation formulas in mild anodization.RSC advances · 2026Review
- Smart Biosensing Nanomaterials for Alzheimer's Disease: Advances in Design and Drug Delivery Strategies to Overcome the Blood-Brain Barrier.Biosensors · 2026Review
- Nanorobots hold PD-L1 and break membrane of colorectal cancer cells for immunotherapy.Nature nanotechnology · 2026Article
- Systematic Investigations of the Huperzine A-Producing Endophytic Fungi ofMolecules (Basel, Switzerland) · 2025Article
- Nanomaterial-based approaches to neurotoxin neutralization in neurodegenerative diseases.Nanomedicine (London, England) · 2025Review
- Nanoscale drug formulations for the treatment of Alzheimer's disease progression.RSC advances · 2025Review
- High-purity CRSC advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the accumulating evidence linking the development of Alzheimer's disease (AD) to the aggregation of Aβ peptides and the emergence of Aβ oligomers, the FDA has approved very few anti-aggregation-based therapies over the past several decades. Here, we report the discovery of an Aβ peptide aggregation inhibitor: an ultra-small nanodot called C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.